Complete financial analysis of Bio-Techne Corporation (TECH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Techne Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tessellis S.p.A. (TSL.MI) Income Statement Analysis – Financial Results
- Surya Roshni Limited (SURYAROSNI.NS) Income Statement Analysis – Financial Results
- Jayjun Cosmetic Co., Ltd. (025620.KS) Income Statement Analysis – Financial Results
- RoodMicrotec N.V. (ROOD.AS) Income Statement Analysis – Financial Results
- Air Products and Chemicals, Inc. (0HBH.L) Income Statement Analysis – Financial Results
Bio-Techne Corporation (TECH)
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | 714.01M | 642.99M | 563.00M | 499.02M | 452.25M | 357.76M | 310.58M | 314.56M | 289.96M | 269.05M | 263.96M | 257.42M | 223.48M | 202.62M | 178.65M | 161.26M | 145.01M | 130.90M | 115.36M | 103.84M | 90.90M | 67.30M | 60.90M | 54.60M | 47.70M | 40.30M | 28.70M | 22.30M | 19.30M | 15.70M | 12.50M |
| Cost of Revenue | 389.34M | 366.89M | 349.10M | 298.18M | 255.50M | 240.52M | 210.85M | 188.46M | 162.36M | 144.97M | 106.35M | 79.47M | 78.76M | 65.03M | 54.46M | 55.49M | 52.89M | 46.67M | 45.72M | 36.81M | 34.89M | 35.40M | 32.51M | 28.42M | 23.33M | 25.00M | 17.80M | 17.00M | 17.10M | 16.80M | 15.20M | 11.80M | 9.60M | 8.90M | 7.30M | 6.10M |
| Gross Profit | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | 473.49M | 432.14M | 374.54M | 336.66M | 307.28M | 251.41M | 231.11M | 235.80M | 224.94M | 214.58M | 208.47M | 204.53M | 176.82M | 156.90M | 141.84M | 126.37M | 109.61M | 98.39M | 86.93M | 80.51M | 65.90M | 49.50M | 43.90M | 37.50M | 30.90M | 25.10M | 16.90M | 12.70M | 10.40M | 8.40M | 6.40M |
| Gross Profit Ratio | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.76% | 78.98% | 79.45% | 79.12% | 77.44% | 79.39% | 78.37% | 75.59% | 75.17% | 75.36% | 77.53% | 72.50% | 73.55% | 72.09% | 68.68% | 64.78% | 62.28% | 58.89% | 56.95% | 53.89% | 53.50% | 51.20% |
| Research & Development | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M | 62.41M | 55.33M | 53.51M | 45.19M | 40.85M | 30.95M | 29.26M | 27.91M | 25.99M | 25.12M | 23.56M | 22.39M | 20.08M | 18.83M | 18.38M | 20.77M | 20.58M | 17.47M | 14.52M | 11.20M | 12.00M | 10.60M | 11.70M | 10.40M | 8.60M | 6.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 396.83M | 352.44M | 339.00M | 289.92M | 240.88M | 236.87M | 240.64M | 153.33M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 25.94M | 33.77M | 35.03M | 19.70M | 27.49M | 0.00 | 45.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 396.83M | 378.38M | 372.77M | 324.95M | 260.58M | 264.36M | 240.64M | 199.24M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 9.20M | 8.70M | 7.60M | 7.70M | 6.60M | 5.60M |
| Other Expenses | 0.00 | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.56M | -3.11M | 7.14M | -1.04M | 830.00K | 693.00K | 0.00 | 960.00K | 960.00K | 1.14M | 1.61M | 1.97M | 1.22M | 1.60M | 1.94M | 8.55M | 8.89M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 11.00M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Operating Expenses | 563.04M | 470.87M | 459.91M | 395.55M | 325.78M | 326.77M | 295.97M | 252.76M | 186.07M | 160.25M | 91.66M | 74.83M | 71.72M | 61.88M | 58.26M | 57.69M | 60.24M | 52.66M | 48.40M | 44.08M | 44.10M | 41.90M | 45.57M | 41.13M | 41.16M | 40.80M | 28.30M | 28.60M | 25.30M | 21.50M | 17.50M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Cost & Expenses | 952.37M | 837.76M | 809.01M | 693.74M | 581.27M | 567.29M | 506.82M | 441.22M | 348.43M | 305.22M | 198.01M | 154.30M | 150.48M | 126.91M | 112.72M | 113.18M | 113.13M | 99.33M | 94.11M | 80.89M | 78.98M | 77.29M | 78.08M | 69.55M | 64.49M | 65.80M | 46.10M | 45.60M | 42.40M | 38.30M | 32.70M | 21.80M | 18.20M | 17.10M | 14.20M | 11.90M |
| Interest Income | 3.32M | 3.41M | 794.00K | 473.00K | 605.00K | 569.00K | 409.00K | 304.00K | 249.00K | 634.00K | 2.68M | 2.65M | 2.64M | 3.75M | 4.38M | 7.63M | 12.19M | 8.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.74M | 11.22M | 11.31M | 13.95M | 19.20M | 21.71M | 10.19M | 7.36M | 1.75M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M | 42.76M | 37.23M | 19.18M | 12.32M | 12.47M | 8.70M | 960.00K | 7.77M | 7.26M | 6.99M | 6.96M | 6.11M | 6.04M | 6.35M | 12.69M | 12.74M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 1.80M | 1.30M | 1.00M | 500.00K | 300.00K | 200.00K |
| EBITDA | 310.37M | 460.57M | 420.12M | 258.47M | 373.91M | 211.89M | 200.60M | 179.36M | 191.99M | 192.93M | 180.57M | 172.98M | 174.66M | 173.68M | 164.58M | 158.55M | 151.55M | 137.01M | 115.46M | 103.87M | 88.31M | 74.07M | 65.51M | 58.54M | 52.00M | 37.00M | 23.50M | 17.60M | 14.10M | 11.10M | 9.40M | 8.20M | 5.10M | 2.70M | 1.80M | 800.00K |
| EBITDA Ratio | 26.78% | 35.73% | 35.97% | 25.49% | 21.31% | 20.55% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 54.18% | 57.59% | 59.86% | 60.04% | 62.96% | 59.90% | 59.84% | 57.52% | 58.79% | 56.19% | 51.16% | 63.41% | 50.75% | 50.07% | 39.71% | 33.14% | 27.75% | 25.09% | 22.85% | 24.32% | 29.97% | 26.01% | 13.47% | 10.83% | 5.60% |
| Operating Income | 206.69M | 298.94M | 296.59M | 149.55M | 74.68M | 125.58M | 136.18M | 121.78M | 150.59M | 147.02M | 159.75M | 158.47M | 166.21M | 163.06M | 156.33M | 150.78M | 144.29M | 124.15M | 108.50M | 97.76M | 82.27M | 67.72M | 52.82M | 45.81M | 39.34M | 25.10M | 21.20M | 15.30M | 12.20M | 9.40M | 7.60M | 6.90M | 4.10M | 2.20M | 1.50M | 600.00K |
| Operating Income Ratio | 17.83% | 26.30% | 26.83% | 16.06% | 10.11% | 17.59% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 51.02% | 52.84% | 56.23% | 58.10% | 57.12% | 56.05% | 55.55% | 53.55% | 54.72% | 51.02% | 46.70% | 40.35% | 39.71% | 37.89% | 27.61% | 31.50% | 25.12% | 22.34% | 19.71% | 18.86% | 24.04% | 18.39% | 11.40% | 9.55% | 4.80% |
| Total Other Income/Expenses | -21.00M | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.62M | -3.11M | 7.14M | 1.64M | 2.19M | -4.01M | 1.93M | 118.00K | 4.58M | 9.54M | 4.78M | 2.66M | 2.12M | 268.00K | 1.84M | -15.08M | 2.00M | 66.98K | 1.00M | 1.20M | 700.00K | 400.00K | 200.00K | -400.00K | -400.00K | -800.00K | 0.00 | -100.00K | 0.00 |
| Income Before Tax | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M | 112.02M | 125.95M | 113.16M | 147.48M | 154.16M | 161.39M | 160.66M | 162.20M | 164.98M | 156.45M | 155.36M | 153.83M | 128.93M | 111.16M | 99.89M | 82.54M | 69.56M | 37.74M | 47.81M | 39.41M | 26.10M | 22.40M | 16.00M | 12.60M | 9.60M | 7.20M | 6.50M | 3.30M | 2.20M | 1.40M | 600.00K |
| Income Before Tax Ratio | 16.02% | 29.79% | 27.26% | 15.92% | 37.43% | 15.69% | 19.59% | 20.10% | 29.55% | 34.09% | 45.11% | 51.73% | 51.56% | 56.90% | 58.15% | 58.86% | 59.76% | 57.69% | 54.86% | 55.91% | 51.19% | 47.97% | 28.83% | 41.44% | 37.96% | 28.71% | 33.28% | 26.27% | 23.08% | 20.13% | 17.87% | 22.65% | 14.80% | 11.40% | 8.92% | 4.80% |
| Income Tax Expense | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M | 15.94M | 602.00K | 35.88M | 43.01M | 46.43M | 50.44M | 48.10M | 49.86M | 52.68M | 46.67M | 50.12M | 50.27M | 43.82M | 37.81M | 33.76M | 29.61M | 24.16M | 10.61M | 13.76M | 12.83M | 9.40M | 7.20M | 5.10M | 4.00M | 2.90M | 2.10M | 2.10M | 1.30M | 600.00K | 400.00K | 200.00K |
| Net Income | 168.11M | 285.26M | 272.05M | 140.41M | 229.30M | 96.07M | 125.35M | 77.29M | 104.48M | 107.74M | 110.95M | 112.56M | 112.33M | 112.30M | 109.78M | 105.24M | 103.56M | 85.11M | 73.35M | 66.13M | 52.93M | 45.40M | 27.13M | 34.05M | 26.58M | 16.70M | 15.20M | 10.90M | 8.60M | 6.70M | 5.10M | 4.40M | 2.00M | 1.60M | 1.00M | 400.00K |
| Net Income Ratio | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.49% | 13.73% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.80% | 39.87% | 40.23% | 38.08% | 36.20% | 37.02% | 32.82% | 31.31% | 20.73% | 29.51% | 25.60% | 18.37% | 22.59% | 17.90% | 15.75% | 14.05% | 12.66% | 15.33% | 8.97% | 8.29% | 6.37% | 3.20% |
| EPS | 1.07 | 1.81 | 1.73 | 0.91 | 1.50 | 0.64 | 0.84 | 0.52 | 0.70 | 0.73 | 0.75 | 0.76 | 0.76 | 0.76 | 0.74 | 0.70 | 0.66 | 0.54 | 0.47 | 0.41 | 0.32 | 0.27 | 0.16 | 0.21 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| EPS Diluted | 1.05 | 1.76 | 1.66 | 0.87 | 1.45 | 0.62 | 0.82 | 0.52 | 0.70 | 0.72 | 0.75 | 0.76 | 0.76 | 0.76 | 0.73 | 0.69 | 0.66 | 0.54 | 0.46 | 0.40 | 0.32 | 0.27 | 0.16 | 0.20 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M | 151.12M | 149.90M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M | 156.56M | 157.62M | 156.20M | 161.44M | 164.18M | 165.48M | 166.03M | 165.75M | 162.50M | 160.94M | 151.62M | 150.34M | 155.54M | 152.35M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
| Weighted Avg Shares Out (Dil) | 160.77M | 161.86M | 164.12M | 161.93M | 157.60M | 155.57M | 152.22M | 150.00M | 149.30M | 148.92M | 148.02M | 147.60M | 148.02M | 148.69M | 149.39M | 151.60M | 156.99M | 158.05M | 158.38M | 163.68M | 166.79M | 168.12M | 170.09M | 170.67M | 168.82M | 165.49M | 156.86M | 155.71M | 155.54M | 153.33M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / September 9, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead...
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS , Sept. 6, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd.
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / September 5, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead...
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or...
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications...
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS , Aug. 30, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead plaintiff applications...
New Strong Sell Stocks for August 30th
AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.
ODDITY TECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, LA / ACCESSWIRE / August 29, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 17, 2024 to file lead...
ODDITY TECH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ODDITY Tech Ltd. - ODD
NEW ORLEANS, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 17, 2024 to file lead plaintiff applications in a securities class action lawsuit against ODDITY Tech Ltd. (“Oddity” or...
New Strong Sell Stocks for August 28th
TECH, AMFPF and B have been added to the Zacks Rank #5 (Strong Sell) List on August 28, 2024.
Source: https://incomestatements.info
Category: Stock Reports